Antidiabetic Agents-WPS Office

## Antidiabetic Agents
Antidiabetic agents are medications used to treat diabetes mellitus by controlling blood glucose levels.
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia due to defects in
insulin secretion, insulin action, or both. The main types of diabetes are type 1 diabetes (T1D), type 2
diabetes (T2D), and gestational diabetes. This overview will focus on the various classes of antidiabetic
agents, their mechanisms of action, and their therapeutic roles.
### Insulin and Insulin Analogues
**1. Insulin:**
Insulin therapy is essential for individuals with T1D and for many with T2D, especially when other
medications are insufficient. Insulin can be categorized based on the duration of action:
- **Rapid-acting Insulins:** (e.g., insulin lispro, aspart, glulisine) act quickly to cover blood sugar spikes
from meals.
- **Short-acting Insulin:** (e.g., regular insulin) is used to control blood sugar levels during meals.
- **Intermediate-acting Insulin:** (e.g., NPH insulin) helps manage blood sugar levels between meals
and overnight.
- **Long-acting Insulins:** (e.g., insulin glargine, detemir) provide a steady insulin level throughout the
day and night.
- **Ultra-long-acting Insulins:** (e.g., insulin degludec) offer an even more prolonged effect.
**Mechanism:** Insulin facilitates glucose uptake by tissues, especially muscle and adipose tissue, and
inhibits hepatic glucose production, thus lowering blood glucose levels.
### Oral Antidiabetic Agents
**2. Biguanides:**
- **Example:** Metformin
- **Mechanism:** Decreases hepatic glucose production and increases insulin sensitivity in peripheral
tissues.
- **Benefits:** Does not cause hypoglycemia when used alone, promotes weight loss or weight
neutrality.
**3. Sulfonylureas:**
- **Examples:** Glipizide, glyburide, glimepiride
- **Mechanism:** Stimulates insulin release from pancreatic beta cells.
- **Benefits:** Effective in lowering blood glucose levels but can cause hypoglycemia and weight gain.
**4. Meglitinides:**
- **Examples:** Repaglinide, nateglinide
- **Mechanism:** Similar to sulfonylureas, they stimulate rapid insulin secretion but with a shorter
duration of action.
- **Benefits:** Lower risk of prolonged hypoglycemia compared to sulfonylureas.
**5. Thiazolidinediones (TZDs):**
- **Examples:** Pioglitazone, rosiglitazone
- **Mechanism:** Increase insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
receptors.
- **Benefits:** Effective in lowering blood glucose, but can cause weight gain, edema, and increased risk
of heart failure.
**6. Alpha-glucosidase Inhibitors:**
- **Examples:** Acarbose, miglitol
- **Mechanism:** Inhibit intestinal enzymes that break down carbohydrates, leading to slower glucose
absorption.
- **Benefits:** Reduces postprandial blood glucose spikes, but may cause gastrointestinal side effects
like flatulence and diarrhea.
**7. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors:**
- **Examples:** Sitagliptin, saxagliptin, linagliptin
- **Mechanism:** Inhibit DPP-4 enzyme, prolonging the action of incretin hormones which increase
insulin release and decrease glucagon levels.
- **Benefits:** Low risk of hypoglycemia, weight-neutral effect.
### Injectable Antidiabetic Agents
**8. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists:**
- **Examples:** Exenatide, liraglutide, dulaglutide, semaglutide
- **Mechanism:** Mimic GLP-1, enhancing insulin secretion, suppressing glucagon release, slowing
gastric emptying, and promoting satiety.
- **Benefits:** Weight loss, low risk of hypoglycemia, improved cardiovascular outcomes in some cases.
### Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors
**9. SGLT2 Inhibitors:**
- **Examples:** Canagliflozin, dapagliflozin, empagliflozin
- **Mechanism:** Inhibit SGLT2 in the kidneys, reducing glucose reabsorption and increasing glucose
excretion in urine.
- **Benefits:** Weight loss, blood pressure reduction, and cardiovascular and renal benefits. Risk of
urinary tract infections and genital mycotic infections.
### Combination Therapies

Combination therapies involve using two or more antidiabetic agents with different mechanisms to
achieve better glycemic control and reduce the risk of adverse effects. Common combinations include:
- Metformin with sulfonylureas
- Metformin with DPP-4 inhibitors
- Metformin with SGLT2 inhibitors
- Metformin with GLP-1 receptor agonists
### Future and Emerging Therapies
Research continues to identify novel targets and develop new antidiabetic agents. Potential future
therapies include:
- **Dual or triple agonists:** Combining the actions of GLP-1, GIP (glucose-dependent insulinotropic
polypeptide), and glucagon receptors.
- **Cell-based therapies:** Using stem cells or pancreatic islet transplantation to restore endogenous
insulin production.
- **Gene therapy:** Targeting genes involved in glucose metabolism and insulin production.
### Conclusion
Antidiabetic agents play a crucial role in managing diabetes, each with unique mechanisms and benefits.
The choice of therapy depends on various factors, including the type of diabetes, patient characteristics,
and comorbidities. Advances in research continue to improve the efficacy and safety of these agents,
offering better outcomes for individuals with diabetes.

Antidiabetic Agents-WPS Office

Uploaded by

Copyright:

Available Formats

Antidiabetic Agents-WPS Office

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Antidiabetic Agents-WPS Office

Uploaded by

Copyright:

Available Formats

## Antidiabetic Agents

### Insulin and Insulin Analogues

### Oral Antidiabetic Agents

- **Examples:** Glipizide, glyburide, glimepiride

- **Mechanism:** Stimulates insulin release from pancreatic beta cells.

- **Examples:** Repaglinide, nateglinide

- **Benefits:** Lower risk of prolonged hypoglycemia compared to sulfonylureas.

**5. Thiazolidinediones (TZDs):**

- **Examples:** Pioglitazone, rosiglitazone

**6. Alpha-glucosidase Inhibitors:**

- **Examples:** Acarbose, miglitol

**7. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors:**

- **Examples:** Sitagliptin, saxagliptin, linagliptin

- **Benefits:** Low risk of hypoglycemia, weight-neutral effect.

### Injectable Antidiabetic Agents

**8. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists:**

- **Examples:** Exenatide, liraglutide, dulaglutide, semaglutide

### Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors

**9. SGLT2 Inhibitors:**

- **Examples:** Canagliflozin, dapagliflozin, empagliflozin

### Combination Therapies

- Metformin with sulfonylureas

- Metformin with DPP-4 inhibitors

- Metformin with SGLT2 inhibitors

- Metformin with GLP-1 receptor agonists

### Future and Emerging Therapies

You might also like

- Examples: Glipizide, glyburide, glimepiride

- Mechanism: Stimulates insulin release from pancreatic beta cells.

- Examples: Repaglinide, nateglinide

- Benefits: Lower risk of prolonged hypoglycemia compared to sulfonylureas.

5. Thiazolidinediones (TZDs):

- Examples: Pioglitazone, rosiglitazone

6. Alpha-glucosidase Inhibitors:

- Examples: Acarbose, miglitol

7. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors:

- Examples: Sitagliptin, saxagliptin, linagliptin

- Benefits: Low risk of hypoglycemia, weight-neutral effect.

8. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists:

- Examples: Exenatide, liraglutide, dulaglutide, semaglutide

9. SGLT2 Inhibitors:

- Examples: Canagliflozin, dapagliflozin, empagliflozin